https://doi.org/10.55788/a3e812a6
The low overall incidence of embolic complications after LA ablation, makes the subject difficult for randomised trials to investigate. This led to the design of an international multicentre registry study aiming to collect insights into incidence, clinical profiles, influence on ablation strategy used and outcomes. The study included 182 centres in 53 countries with personally invited investigators [1].
The registry included a reference population (RP) consisting of all 304949 ablations (AF and LA flutter) between 2017 and 2023, as well as 491 included cases of symptomatic arterial embolisms happening within the first month post-ablation. In the RP, 53% of patients had paroxysmal AF and 68% received their first ablation, performed in 71% with radiofrequency (RF), 25% cryoballoon (CB), 4% pulsed field ablation (PFA), <1% laser balloon. The corresponding characteristics of the embolism group showed 46% of paroxysmal AF, 79% of first ablations and the use of RF in 69%, CB in 23%, PFA in 6% and laser in 2%. Dr Sergio Castrejon (La Paz University Hospital, Madrid, Spain) commented that cases with higher baseline risk somewhat clustered in the RF group in which procedures tended to be longer and had more ablations beyond the primary veins.
The overall incidence was 0.16 cases/procedure. Looking at the time-to-event, 78% of embolism were diagnosed in under 72 hours after the ablation. “Notably, 15% of cases were detected during the procedure,” Dr Castrejón informed. Neurologic diagnoses were stroke in 324 patients and transient ischaemic attack (TIA) in 137, with limb weakness, aphasia and dysarthria as most common symptoms. The underlying cause was an occlusion of the middle cerebral artery in 53.4% of cases. Dr Castrejón pointed outthat most symptoms were severe. There were also 34 cases of peripheral embolisms, and 3 patients had a combination of brain and coronary embolisms. “In the follow-up after 3 months, which was available in 94% of patients, roughly 40% had some degree of neurological disability and almost 3% died directly as a consequence of the embolism,” Dr Castrejón stated [1].
A further analysis also identified several predictors. Patients ablated for non-paroxysmal AF had a higher incidence of embolisms than those with paroxysmal AF (P<0.001). Furthermore, centres with fewer than 92 procedures per year were linked to higher embolism-incidence. Finally, in comparisons of different energy sources for ablation, incidence of embolisms was higher with laser vs the others (P<0.001) and thermal ablation vs PFA (P=0.02), respectively.
- Castrejón S, et al. Worldwide incidence, management and outcome of systemic embolism following atrial fibrillation ablation: preliminary results from the EMBOL-AF registry. Late-breaking science 4, EHRA 2025, 30 March-01 April, Vienna, Austria.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« S-ICD: an alternative for sudden cardiac death prevention in Brugada syndrome Next Article
Ablation for paroxysmal AF: endpoint of non-inferiority of vHPSD to cryoballoon not met »
« S-ICD: an alternative for sudden cardiac death prevention in Brugada syndrome Next Article
Ablation for paroxysmal AF: endpoint of non-inferiority of vHPSD to cryoballoon not met »
Table of Contents: EHRA 2025
Featured articles
Symptomatic embolisms after AF ablation: new insights on outcomes and predictors
Marked clinical benefit by MPP compared with BVP
Diagnostics, Monitoring, and Prevention
Myocardial fibrosis triples arrhythmia risk in NICM patients
SafeHeart predicts arrhythmias and clinical deterioration
Atrial fibrillation screening: beneficial in high-risk patients
Educational e-mail before AF conversion treatment ups anti-coagulation adherence
AF and dementia: largest Mediterranean cohort reveals age-dependent association
Atrial Fibrillation
PFA non-inferior to CBA in symptomatic paroxysmal atrial fibrillation
Paroxysmal AF ablation: dual energy catheter demonstrates benefit at 12 months
Ablation for paroxysmal AF: endpoint of non-inferiority of vHPSD to cryoballoon not met
Symptomatic embolisms after AF ablation: new insights on outcomes and predictors
Ventricular Arrhythmias
S-ICD: an alternative for sudden cardiac death prevention in Brugada syndrome
PFA shows potential in safety and efficacy of catheter ablations for ventricular arrhythmias
Electrical storm patients at increased risk of VT recurrence after catheter success
Treatment of VT: iATP shows promising results in the fast ventricular tachycardia zone
Devices & Resynchronisation Therapy
Marked clinical benefit by MPP compared with BVP
Landmark Chinese trial reveals that LBBP slashes hospitalisation
Need for post-TAVI pacemaker implantation linked to poorer outcomes
Anticoagulation & Left Atrial Appendage Closure
Apixaban vs aspirin: more bleedings overall but fewer at critical sites
SWISS-APERO demonstrates comparable safety, potential efficacy edge for Amulet
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com